Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To test whether tight glucose control is associated with better clinical outcome compared to less-tight control, among diabetic patients hospitalized in internal medicine wards.
Patient characteristics:
Patients admitted to internal medicine departments in public hospitals of Israel who have pre-admission diagnosis of diabetes, or have a random plasma glucose >200 mg/dl on admission
Eligibility criteria
Exclusion criteria
Process of patient recruitment and randomization:
Protocol:
Basal bolus insulin treatment will be applied to achieve tight glucose target (mean fasting blood glucose<130 mg/dl and not above 180 mg/dl during the day) compared to patients treated to achieve less tight glucose targets (mean fasting blood glucose<200 mg/dl and not above 220 mg/dl during the day)will influence cardiovascular and general clinical outcome.
Primary outcome: All-cause mortality (including in-hospital and up to 12 months post discharge) or re-admission to hospital
Secondary outcomes:
Total number of in-hospital days during one year follow-up (including the index hospital admission)
The rate of any major clinical events (all-cause mortality, hospital acquired infection, organ failure, need of ventilation support, need of vasoactive amine administration, need of central line insertion, hospital admission for stroke, acute coronary event, severe bacterial or fungal infection) during one year follow-up
Hypoglycemic events during index hospital stay.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| tight control | Experimental |
| |
| standard control | Experimental | basal bolus insulin regimen |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Basal bolus insulin regimen (tight glucose control) | Drug | Basal bolus insulin regimen |
| |
| Measure | Description | Time Frame |
|---|---|---|
| All-cause mortality (including in-hospital and up to 12 months post discharge) or re-admission to hospital | 1.5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Total # of in-hospital days during 1 year follow-up.The rate of any major clinical events during 1 year follow-up. Hypoglycemic events during index hospital stay | 1.5 |
Not provided
Inclusion Criteria:
Age: >18 years
Fasting plasma glucose > 140 mg/dl or non-fasting plasma glucose >200 mg/dl in two separate blood tests if non-diabetic, or in a single blood test if have pre-diagnosed diabetes
Able to understand the study objective and methods and willing to provide a written informed consent
No significant liver disease
Serum creatinine <2.0 mg/dl
-
Exclusion Criteria:
Significant cognitive impairment
History of hypoglycemia unawareness or clinical autonomic diabetic neuropathy
Known allergy to insulin analogues
Diabetic ketoacidosis or non-ketotic hyperosmolar coma on admission
-
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Andreas E Buchs, MD | Contact | 972-57-7345025 | abuchs@asaf.health.gov.il |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Assaf Harofeh Medical Center | Ẕerifin | 70300 | Israel |
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Basal bolus insulin regimen (standard control) |
| Drug |
basal bolus insulin regimen |
|